To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected]
ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of cardiovascular emergencies, announces the initiation of the coverage of its title by Gilbert Dupont and Kepler Cheuvreux.
With a study titled “The Best Hope Against Stroke,” Gilbert Dupont initiates coverage of Acticor Biotech with a recommendation to buy.
Kepler Cheuvreux began tracking the title by recommending purchase in an introductory study titled “Holy grail of stroke treatments”.